EN DE
Watch Nuvation Bio Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nuvation Bio Inc (NUVB) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Nuvation Bio Inc stock $2.97, price $3.84, that is 22.7% below the price, quality 45 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US67080N1019

NB Nuvation Bio Inc logo Thin data Nov 16, 2026

Nuvation Bio Inc

NUVB · US

Expensive (fair value 23% below the price), weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Recent news mostly positive 
Quality 45/100 
Price moving sideways (no uptrend) 
Mixed Growth (revenue YoY +699.0 %/yr in USD) 
Insiders bought $118,250 (6M) · sold $2.1M 
Fair value $2.97 · Overvalued 
Loss-making · -88.2% net margin (TTM) 
Negative free cash flow 
Trails peers (3/9) 
Narrow moat 10/100 · thin data
Thin data 
Estimate
Watch Nuvation Bio Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$10.05 $0.9640 Fair Value $2.97 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range $0.9640 – $10.05 · fair‑value band $2.23 – $3.71 · the $3.84 price screens above the $2.97 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Nuvation Bio in your weekly email

Every Wednesday you see whether Nuvation Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.

Show moreShow less

It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo.

The company was founded in 2018 and is headquartered in New York, New York.

Stock analysis

Nuvation Bio Inc (NUVB) currently trades at $3.84, while our estimate is $2.97, 23% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $2.23 (bear) to $3.71 (bull), the price of $3.84 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Nuvation Bio Inc reported revenue of $62.9M in FY2025 versus $0 in FY2021. Reported net income was −$205M in FY2025.

Key figures

Market cap $1.3B Small · P/S ratio 9.78 · EPS (TTM) $−0.4400 · Net margin −88.2% · Return on equity −47.8% · Return on assets (EBIT) −38.3% (5-year average) · Operating margin −161% · Revenue (TTM) $170M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 60% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −23%, NUVB screens richer than that median.

Fair Value

Bear $2.23 Fair Value $2.97 Bull $3.71
Price $3.84 · Downside -22.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 99
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 3
How calm the share price moves, does not count
Price momentum 18
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 29
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $118,250, on Jun 9, 2026. Over the same period, 4 people sold shares worth $2.1M.

  • SaleGary HattersleyCHIEF SCIENTIFIC OFFICER2× since Nov 20, 2025: 469,051 shares, avg. $7.20$3.4MAug 19, 2026
  • SaleKerry WentworthCHIEF REGULATORY OFFICER3× since Apr 6, 2026: 299,750 shares, avg. $4.90$1.5MJun 23, 202610b5-1 plan
  • SaleStacy MarkelCHIEF PEOPLE OFFICER125,000 shares at $6.03$753,750Jun 23, 202610b5-1 plan
  • SalePhilippe SauvageChief Financial Officer47,668 shares at $6.01$286,485Jun 23, 202610b5-1 plan
  • BuyRobert MashalDirector25,000 shares at $4.73$118,250Jun 9, 2026
  • SaleDongfang LiuCHIEF MEDICAL OFFICER5× since Nov 17, 2025: 270,000 shares, avg. $6.92$1.9MApr 17, 2026
  • SaleDavid C. HanleyCHIEF TECHNICAL OPERATIONS200,000 shares at $7.14$1.4MNov 19, 2025

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NUVB screens overvalued: fair value 23% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Nuvation Bio Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −22.7% · Above median
Profitability
Return on assets −34.4% · Below median
Net margin (12 months) −88.2% · Bottom 25%
Operating margin (12 months) −161.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 555.6% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.41× · Pricier than median
P/S (12 months) 7.94× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)3 · sector 1
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs NUVB
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs NUVB
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs NUVB
argenx SE ARGX $950.95 $908.40 −4% vs NUVB
CSL Limited CSL A$199.55 A$186.49 −7% vs NUVB
Moderna, Inc MRNA $215.27 $135.64 −37% vs NUVB
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs NUVB
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs NUVB
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs NUVB
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs NUVB

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nuvation Bio Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Nuvation Bio Inc Fair Value". https://www.fairvalue-calculator.com/stock/NUVB

Frequently asked questions

Is Nuvation Bio Inc (NUVB) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is $2.97 versus a price of $3.84, about 23% lower (overvalued).
What is the fair value of NUVB?
Our estimate for Nuvation Bio Inc is $2.97 (as of Nov 16, 2026), built from audited fundamentals. The current price: $3.84.
What is the quality score of NUVB?
Nuvation Bio Inc has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nuvation Bio Inc (NUVB)?
Our calculated price target is the estimate of $2.97 (as of Nov 16, 2026). Cautious scenario $2.23, optimistic scenario $3.71. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Nuvation Bio Inc stock forecast for 2026?
Our estimate puts fair value at $2.97, about 23% lower versus a price of $3.84 (overvalued). Cautious scenario $2.23, optimistic scenario $3.71. The calculation is refreshed regularly with new filings.
What is the revenue of Nuvation Bio Inc (NUVB)?
Nuvation Bio Inc reported trailing-twelve-month revenue of about $170M (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Nuvation Bio Inc (NUVB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nuvation Bio Inc it is $2.97 per share (as of Nov 16, 2026), against a price of $3.84.
Is Nuvation Bio Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, NUVB trades above its calculated fair value: price $3.84, fair value $2.97, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NUVB?
No. The price is what the market pays today ($3.84); the fair value is what the company's own numbers justify ($2.97). For Nuvation Bio Inc the two are $0.8700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nuvation Bio Inc worth?
The market values Nuvation Bio Inc at about $1.3B (market capitalisation, as of Nov 16, 2026). Per share that is $3.84; our models calculate a fair value of $2.97 per share.
What do the bullish and bearish scenarios say about NUVB?
Our models span a range for Nuvation Bio Inc: cautious scenario $2.23, base $2.97, optimistic $3.71 per share (as of Nov 16, 2026, price $3.84). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nuvation Bio Inc (NUVB)?
Balance-sheet figures for Nuvation Bio Inc (as of Nov 16, 2026): return on equity −47.8%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is NUVB from its 52-week high?
Nuvation Bio Inc trades at $3.84, about 60% below its 52-week high of $9.54 and at the low of $3.84 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $2.97 is for.
Which stocks are comparable to Nuvation Bio Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nuvation Bio Inc stock attractive at the current price?
The data as of Nov 16, 2026: price $3.84, calculated fair value $2.97 (−23%), Quality Score 45/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Nuvation Bio Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nuvation Bio Inc (NUVB)?
The closing price on Nov 16, 2026 was $3.84. Our estimate is $2.97, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nuvation Bio Inc right now?
The price sits above even our optimistic bull case ($3.71). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Nuvation Bio Inc

How large is the market capitalisation of Nuvation Bio Inc (NUVB)?
The market capitalisation of Nuvation Bio Inc is $1.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nuvation Bio Inc (NUVB)?
The price-to-sales ratio of Nuvation Bio Inc is 9.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nuvation Bio Inc (NUVB)?
Earnings per share at Nuvation Bio Inc are $−0.4400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Nuvation Bio Inc (NUVB)?
The net margin of Nuvation Bio Inc is −88.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nuvation Bio Inc (NUVB)?
The return on equity (ROE) of Nuvation Bio Inc is −47.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nuvation Bio Inc (NUVB)?
On an EBIT basis the return on assets of Nuvation Bio Inc is −38.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nuvation Bio Inc (NUVB)?
The operating margin of Nuvation Bio Inc is −161% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nuvation Bio Inc (NUVB)?
Revenue at Nuvation Bio Inc is growing 556% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Nuvation Bio Inc (NUVB) generate?
The free cash flow of Nuvation Bio Inc is −$174M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Nuvation Bio Inc (NUVB) hold?
Nuvation Bio Inc holds more cash than debt, $154M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Nuvation Bio Inc in the live analysis

One click puts Nuvation Bio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.